Regeneron Pharmaceuticals, headquartered in Tarrytown, received FDA approval for a gene therapy on May 28, 2026.
4 reports, 2 independent
Updated Aug 19
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Regeneron Pharmaceuticals, headquartered in Tarrytown, received FDA approval for a gene therapy on May 28, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Regeneron Pharmaceuticals
American pharmaceutical company
Related events
- FDA placed a clinical hold on a gene therapy involving Hunter.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
Coverage
Newest first; wire copies grouped- wibx950.com
- Clinical Trials ArenaRegeneron tees up myasthenia gravis drug approval after Phase III victory Regeneron is eyeing regulatory approval for its subcutaneous generalised myasthenia gravis (gMG) candidate cemdisiran after p
- Unknown outlet